309 related articles for article (PubMed ID: 28646535)
1. Targeting STAT3 by HO3867 induces apoptosis in ovarian clear cell carcinoma.
Bixel K; Saini U; Kumar Bid H; Fowler J; Riley M; Wanner R; Deepa Priya Dorayappan K; Rajendran S; Konishi I; Matsumura N; Cohn DE; Selvendiran K
Int J Cancer; 2017 Nov; 141(9):1856-1866. PubMed ID: 28646535
[TBL] [Abstract][Full Text] [Related]
2. Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target.
Saini U; Naidu S; ElNaggar AC; Bid HK; Wallbillich JJ; Bixel K; Bolyard C; Suarez AA; Kaur B; Kuppusamy P; Hays J; Goodfellow PJ; Cohn DE; Selvendiran K
Oncogene; 2017 Jan; 36(2):168-181. PubMed ID: 27292260
[TBL] [Abstract][Full Text] [Related]
3. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition.
Selvendiran K; Ahmed S; Dayton A; Kuppusamy ML; Rivera BK; Kálai T; Hideg K; Kuppusamy P
Cancer Biol Ther; 2011 Nov; 12(9):837-45. PubMed ID: 21885917
[TBL] [Abstract][Full Text] [Related]
4. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
Chan KK; Wong OG; Wong ES; Chan KK; Ip PP; Tse KY; Cheung AN
Int J Cancer; 2018 Sep; 143(6):1456-1469. PubMed ID: 29663364
[TBL] [Abstract][Full Text] [Related]
5. Aberrantly activated pSTAT3-Ser727 in human endometrial cancer is suppressed by HO-3867, a novel STAT3 inhibitor.
Tierney BJ; McCann GA; Naidu S; Rath KS; Saini U; Wanner R; Kuppusamy P; Suarez A; Goodfellow PJ; Cohn DE; Selvendiran K
Gynecol Oncol; 2014 Oct; 135(1):133-41. PubMed ID: 25038288
[TBL] [Abstract][Full Text] [Related]
6. c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma.
Kim HJ; Yoon A; Ryu JY; Cho YJ; Choi JJ; Song SY; Bang H; Lee JS; Cho WC; Choi CH; Lee JW; Kim BG; Bae DS
Sci Rep; 2016 Dec; 6():38502. PubMed ID: 27917934
[TBL] [Abstract][Full Text] [Related]
7. The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma.
Oishi T; Itamochi H; Kudoh A; Nonaka M; Kato M; Nishimura M; Oumi N; Sato S; Naniwa J; Sato S; Shimada M; Kigawa J; Harada T
Oncol Rep; 2014 Aug; 32(2):553-8. PubMed ID: 24927217
[TBL] [Abstract][Full Text] [Related]
8. HO-3867, a STAT3 inhibitor induces apoptosis by inactivation of STAT3 activity in BRCA1-mutated ovarian cancer cells.
Tierney BJ; McCann GA; Cohn DE; Eisenhauer E; Sudhakar M; Kuppusamy P; Hideg K; Selvendiran K
Cancer Biol Ther; 2012 Jul; 13(9):766-75. PubMed ID: 22801507
[TBL] [Abstract][Full Text] [Related]
9. HNF1β drives glutathione (GSH) synthesis underlying intrinsic carboplatin resistance of ovarian clear cell carcinoma (OCCC).
Lopes-Coelho F; Gouveia-Fernandes S; Gonçalves LG; Nunes C; Faustino I; Silva F; Félix A; Pereira SA; Serpa J
Tumour Biol; 2016 Apr; 37(4):4813-29. PubMed ID: 26520442
[TBL] [Abstract][Full Text] [Related]
10. Anticancer potential of diarylidenyl piperidone derivatives, HO-4200 and H-4318, in cisplatin resistant primary ovarian cancer.
ElNaggar AC; Saini U; Naidu S; Wanner R; Sudhakar M; Fowler J; Nagane M; Kuppusamy P; Cohn DE; Selvendiran K
Cancer Biol Ther; 2016 Oct; 17(10):1107-1115. PubMed ID: 27415751
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary.
Yanaihara N; Hirata Y; Yamaguchi N; Noguchi Y; Saito M; Nagata C; Takakura S; Yamada K; Okamoto A
Mol Carcinog; 2016 May; 55(5):832-41. PubMed ID: 25856562
[TBL] [Abstract][Full Text] [Related]
12. Anticancer efficacy of a difluorodiarylidenyl piperidone (HO-3867) in human ovarian cancer cells and tumor xenografts.
Selvendiran K; Tong L; Bratasz A; Kuppusamy ML; Ahmed S; Ravi Y; Trigg NJ; Rivera BK; Kálai T; Hideg K; Kuppusamy P
Mol Cancer Ther; 2010 May; 9(5):1169-79. PubMed ID: 20442315
[TBL] [Abstract][Full Text] [Related]
13. OSI-906 restores the sensitivity of ovarian clear cell carcinoma to cisplatin by targeting the IGF1R/AKT pathway.
Liu L; Liang C; Zhuo C; Jiang H; Ye H; Ruan T; Song J; Jiang S; Zhang Y; Li X
Med Oncol; 2022 Jan; 39(2):26. PubMed ID: 34982265
[TBL] [Abstract][Full Text] [Related]
14.
Kawahara N; Yamada Y; Kobayashi H
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070839
[TBL] [Abstract][Full Text] [Related]
15. Targeting an autocrine IL-6-SPINK1 signaling axis to suppress metastatic spread in ovarian clear cell carcinoma.
Mehner C; Miller E; Hockla A; Coban M; Weroha SJ; Radisky DC; Radisky ES
Oncogene; 2020 Oct; 39(42):6606-6618. PubMed ID: 32929152
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.
Kuroda T; Ogiwara H; Sasaki M; Takahashi K; Yoshida H; Kiyokawa T; Sudo K; Tamura K; Kato T; Okamoto A; Kohno T
Gynecol Oncol; 2019 Dec; 155(3):489-498. PubMed ID: 31604667
[TBL] [Abstract][Full Text] [Related]
17. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis.
Rosen DG; Mercado-Uribe I; Yang G; Bast RC; Amin HM; Lai R; Liu J
Cancer; 2006 Dec; 107(11):2730-40. PubMed ID: 17063503
[TBL] [Abstract][Full Text] [Related]
18. Targeting PDGF signaling of cancer-associated fibroblasts blocks feedback activation of HIF-1α and tumor progression of clear cell ovarian cancer.
Mori Y; Okimoto Y; Sakai H; Kanda Y; Ohata H; Shiokawa D; Suzuki M; Yoshida H; Ueda H; Sekizuka T; Tamura R; Yamawaki K; Ishiguro T; Mateos RN; Shiraishi Y; Yatabe Y; Hamada A; Yoshihara K; Enomoto T; Okamoto K
Cell Rep Med; 2024 May; 5(5):101532. PubMed ID: 38670097
[TBL] [Abstract][Full Text] [Related]
19. Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth.
Gritsina G; Xiao F; O'Brien SW; Gabbasov R; Maglaty MA; Xu RH; Thapa RJ; Zhou Y; Nicolas E; Litwin S; Balachandran S; Sigal LJ; Huszar D; Connolly DC
Mol Cancer Ther; 2015 Apr; 14(4):1035-47. PubMed ID: 25646015
[TBL] [Abstract][Full Text] [Related]
20. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer.
Han Z; Hong Z; Gao Q; Chen C; Hao Z; Ji T; Hu W; Yan Y; Feng J; Liao S; Wu P; Wang D; Wang S; Zhou J; Ma D
Hum Gene Ther; 2012 Jan; 23(1):32-45. PubMed ID: 21875334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
